Comparative Study of Chemoport Versus Peripheral Venous Access in Breast Cancer Patients

Dr Rohith Yadav G

doi:10.63363/aijfr.2026.v07i04.7312

Comparative Study of Chemoport Versus Peripheral Venous Access in Breast Cancer Patients

Author(s)	1 Dr Rohith Yadav G
Country	India
Abstract	Abstract Background: Reliable venous access is an important component of systemic treatment for breast cancer, particularly when patients require repeated administration of adjuvant chemotherapy or neoadjuvant chemotherapy (NACT). Totally implantable venous access devices (TIVADs), commonly referred to as chemoports, provide durable central venous access while avoiding repeated peripheral venepuncture. Methods: A prospective comparative study was conducted over six months among patients with carcinoma breast receiving adjuvant chemotherapy or NACT. Eighty patients were included according to the study dataset specified for this manuscript: 40 received chemotherapy through a TIVAD and 40 through peripheral intravenous access. Port implantation time, early and postoperative complications, hospital discharge, and clinical experience regarding chemotherapy administration and patient compatibility were assessed. Results: The mean duration of chemoport implantation was approximately 40 minutes. Approximately 90% of patients were discharged within 48 hours without complications. Reported complications associated with port placement or use included arterial puncture, hematoma, port blockage, catheter malposition, deep venous thrombosis, pneumothorax, hemothorax, local port-site infection, sepsis, and port blockage during chemotherapy. Compared with peripheral access, TIVAD use was associated with better practical acceptability, fewer repeated venepunctures, and improved convenience for repeated chemotherapy administration. Conclusion: TIVADs offer a reliable and patient-compatible option for breast cancer patients requiring repeated intravenous chemotherapy. Although port insertion carries recognized mechanical, thrombotic, infectious, and procedure-related risks, these complications can be minimized by appropriate patient selection, meticulous technique, radiological guidance where appropriate, and experienced surgical practice. Prospective studies with standardized patient-reported outcomes and quantified complication rates are warranted.
Keywords	breast cancer; chemotherapy; totally implantable venous access device; chemoport; peripheral intravenous access; thrombophlebitis; venous access; complications
Field	Medical / Pharmacy
Published In	Volume 7, Issue 4, July-August 2026
Published On	2026-08-13
DOI	https://doi.org/10.63363/aijfr.2026.v07i04.7312

View / Download PDF File

E-ISSN 3048-7641

doi

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 4 Cover Page Vol 7 Isu 3 Cover Page Vol 7 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About AIJFR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-79-39-59	editor@aijfr.com

Advanced International Journal for Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Comparative Study of Chemoport Versus Peripheral Venous Access in Breast Cancer Patients

Share this